quinazolines has been researched along with cp 724714 in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, F; Letrent, SP; Sharma, A | 1 |
| Britten, CD; Denis, L; Gelmon, K; Guo, F; Letrent, SP; Minton, SE; Mita, M; Moulder, S; Munster, PN; Slamon, DJ; Tolcher, AW | 1 |
| Britten, CD; Gelmon, K; Guo, F; Letrent, SP; Munster, PN; Sharma, A; Tolcher, AW | 1 |
| Bhattacharya, SK; Campbell, M; Coleman, KG; Connell, RD; Currier, N; Emerson, EO; Finn, RS; Floyd, E; Harriman, S; Jani, JP; Kath, JC; Morris, J; Moyer, JD; Pustilnik, LR; Rafidi, K; Ralston, S; Rossi, AM; Steyn, SJ; Wagner, L; Winter, SM | 1 |
| Bi, YA; Campbell, S; Davidson, R; Duignan, DB; Dunn, MC; Feng, B; Kostrubsky, VE; Mireles, R; Smith, AR; Wang, HF; Xu, JJ | 1 |
| Duan, H; Han, Y; Huang, D; Huang, H; Qu, L; Ru, G; Shou, C; Tong, X; Zhao, Z | 1 |
| Birkeland, AC; Bradford, CR; Brenner, JC; Carey, TE; Foltin, SK; Komarck, CM; Ludwig, ML; Mann, JE; McHugh, JB; Michmerhuizen, NL; Prince, ME; Sandelski, MM; Scott, MV; Spector, ME; Tillman, BN; Yanik, M | 1 |
| Block, CJ; Chen, W; Craig, DB; Dong, L; Jang, H; Meng, F; Mitchell, AV; Wu, G; Wu, L; Yang, Q; Zhang, B | 1 |
| Brenner, JC; Carey, TE; Harris, M; Herbst, G; Jiang, H; Kulkarni, A; Leonard, E; Matovina, C; Michmerhuizen, NL; Zhai, J | 1 |
| Bindhya, S; Ganesan, TS; Joshua, T; Krishnapriya, S; Manasa, P; Murhekar, K; Nagare, RP; Shabna, A; Sidhanth, C; Sneha, S | 1 |
| Hitaoka, S; Inoue, K; Kikuchi, K; Komori, T; Kusano, K; Takahashi, K | 1 |
3 trial(s) available for quinazolines and cp 724714
| Article | Year |
|---|---|
Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Body Weight; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Female; Humans; Liver Neoplasms; Middle Aged; Models, Biological; Multicenter Studies as Topic; Neoplasms; Nonlinear Dynamics; Quinazolines; Receptor, ErbB-2; Tissue Distribution | 2007 |
First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2007 |
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chromatography, Liquid; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Half-Life; Humans; Liver Function Tests; Middle Aged; Neoplasm Metastasis; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Tandem Mass Spectrometry | 2008 |
8 other study(ies) available for quinazolines and cp 724714
| Article | Year |
|---|---|
Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Growth Processes; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mice; Mice, Nude; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2007 |
Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bile; Bile Acids and Salts; Calcium; Carrier Proteins; Cells, Cultured; Chemical and Drug Induced Liver Injury; Enzyme Inhibitors; Fluoresceins; Hepatocytes; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Membrane Potentials; Mitochondrial Membranes; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Quinazolines; Receptor, ErbB-2 | 2009 |
Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Snail Family Transcription Factors; Stomach Neoplasms; Survival Analysis; Up-Regulation | 2016 |
Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.
Topics: Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Carbamates; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; ErbB Receptors; Gene Expression Profiling; Humans; Hydroxybutyrates; Immunohistochemistry; Laryngeal Neoplasms; Mouth Neoplasms; Mutation; Purines; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Triazines | 2016 |
Cooperative oncogenic effect and cell signaling crosstalk of co‑occurring HER2 and mutant PIK3CA in mammary epithelial cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromones; Chromosomes, Human, Pair 17; Class I Phosphatidylinositol 3-Kinases; DNA Replication; Female; Gene Amplification; Genome-Wide Association Study; Humans; Mammary Glands, Human; Morpholines; Mutation; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2017 |
Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Topics: Afatinib; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Sulfonamides | 2019 |
LASP-1 interacts with ErbB2 in ovarian cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Adult; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cohort Studies; Cytoskeletal Proteins; Female; HEK293 Cells; Humans; Lapatinib; LIM Domain Proteins; Middle Aged; Ovarian Neoplasms; Phosphorylation; Plasmids; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection | 2022 |
In Vitro Metabolism of 2-Methoxy-N-[3-[4-[3-methyl-4-[(6-methyl- 3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide (CP-724,714) by Aldehyde Oxidase and Predicting Its Percent Contribution Relative to CYP-Mediated Metabolism.
Topics: Acetamides; Aldehyde Oxidase; Cytochrome P-450 Enzyme System; Humans; Quinazolines | 2023 |